# A Study of GDC-0853 in Participants With Refractory Chronic Spontaneous Urticaria (CSU).

> **NCT03137069** · PHASE2 · COMPLETED · sponsor: **Genentech, Inc.** · enrollment: 134 (actual)

## Conditions studied

- Urticaria

## Interventions

- **DRUG:** GDC-0853
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03137069
- **Lead sponsor:** Genentech, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-05-26
- **Primary completion:** 2019-09-27
- **Final completion:** 2019-10-25
- **Target enrollment:** 134 (ACTUAL)
- **Last updated:** 2020-09-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03137069

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03137069, "A Study of GDC-0853 in Participants With Refractory Chronic Spontaneous Urticaria (CSU).". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT03137069. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*